Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

RAS-targeted therapies: is the undruggable drugged?

AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Integrated proteogenomic characterization across major histological types of pediatric brain cancer

F Petralia, N Tignor, B Reva, M Koptyra, S Chowdhury… - Cell, 2020 - cell.com
We report a comprehensive proteogenomics analysis, including whole-genome sequencing,
RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 …

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

C Fedele, S Li, KW Teng, CJR Foster, D Peng… - Journal of Experimental …, 2020 - rupress.org
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

Targeting alterations in the RAF–MEK pathway

R Yaeger, RB Corcoran - Cancer discovery, 2019 - AACR
The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer.
Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in …

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

I Landa, T Ibrahimpasic, L Boucai… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer
(ATC) are rare and frequently lethal tumors that so far have not been subjected to …

Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident

LM Morton, DM Karyadi, C Stewart, TI Bogdanova… - Science, 2021 - science.org
INTRODUCTION The 1986 Chernobyl (Chornobyl in Ukrainian) nuclear power plant
accident exposed millions of individuals in the surrounding region to radioactive …

Integrated genomic characterization of papillary thyroid carcinoma

N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi… - Cell, 2014 - cell.com
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …